Research programme: therapeutic agents - Bayer/CenixAlternative Names: Therapeutic agents research programme - Bayer/Cenix
Latest Information Update: 19 Jul 2005
At a glance
- Originator Bayer HealthCare; Cenix BioScience
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 19 Jul 2005 Discontinued - Preclinical for Undefined in Germany (unspecified route)
- 23 Dec 2003 Preclinical trials in Undefined in Germany (unspecified route)